CYTORA LTD

General Data

supplementary funding
Reg Number
515246775
Sector
Biomed
Established
2015
No. of Employees
14
Stage
R&D
Additional Funding
1

Description

• CYTORA is a clinical stage stem-cell company developing a new class of “Off the Shelf” medicines based on a novel & transformative patented platform technology derived from unique human Oral Mucosa Stem Cells (hOMSC).

Technology

Cytora's platform is built on human oral mucosa stem cells (hOMSC), a stem cell population discovered in the lamina propria of the oral mucosa that retains properties of neural crest and mesenchymal stem cells. The cells act through a dual mechanism of direct cell engraftment/replacement and paracrine trophic signaling that modulates the surrounding tissue microenvironment, supporting scar-free, fetal-like tissue regeneration and reduced neuroinflammation in preclinical models. hOMSC exhibit allogeneic immune properties that avoid the need for immunosuppression, remain non-tumorigenic and non-immunogenic, and produce consistent results across donors regardless of age, gender, or diabetic status. A minimal oral mucosa biopsy can be expanded via a defined culture process into enough cells to manufacture thousands of allogeneic, off-the-shelf doses. The lead formulation, hOMSC200, is administered locally for chronic wound indications; hOMSC300 is administered intrathecally via lumbar puncture for neurological indications, using a controlled infusion protocol (the subject of the company's own issued patent) designed to reduce administration-related side effects while enabling higher therapeutic cell doses.

Targeted Customers

Healthcare providers, wound-care and podiatry clinics, and hospital systems treating chronic diabetic foot ulcers and neurodegenerative disease patients.

Management personnel

Yona Geffen - CEO

Contact information

Name
Jacob Zankel
Phone
0544458530
Website
http://www.cytorastem.com
Country
Israel
Zip
5229054

Tags

BiologicalsBiotechnologyLife SciencesMedTech

Classified Technologies

Pharma
Biotechnology
Biomedicine and pharmaceuticals

Winning details

Route name
Winning year

The Expedited Program
The Expedited Program
2023
Development to manufactor
Development to manufactor
2025